<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148391</url>
  </required_header>
  <id_info>
    <org_study_id>NYX-458-2006</org_study_id>
    <nct_id>NCT04148391</nct_id>
  </id_info>
  <brief_title>NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)</brief_title>
  <official_title>A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptinyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CogState Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aptinyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia&#xD;
      Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a 16 to 18-week study, including a 2 to 4-week screening period, followed&#xD;
      by a 12-week double-blind, randomized, placebo-controlled treatment Period, and a 2-week&#xD;
      follow-up period. Subjects eligible for the study will be randomized to receive either&#xD;
      NYX-458 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in physical examination</measure>
    <time_frame>Subjects will be followed up to 14 days post-dose</time_frame>
    <description>Physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of adverse events and serious adverse events</measure>
    <time_frame>Subjects will be followed up to 14 days post-dose</time_frame>
    <description>Adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of early termination due to adverse events</measure>
    <time_frame>Subjects will be followed up to 14 days post-dose</time_frame>
    <description>Early termination due to adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital signs, clinical laboratory values, and electrocardiogram results</measure>
    <time_frame>Subjects will be followed up to 14 days post-dose</time_frame>
    <description>Vital signs, clinical laboratory values, and electrocardiogram results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline dissociative effects, psychosis, and hallucinatory symptoms as measured by the Neuropsychiatric Inventory (NPI-12)</measure>
    <time_frame>Subjects will be followed up to 14 days post-dose</time_frame>
    <description>Neuropsychiatric Inventory (NPI-12) - NPI-12 assesses 12 behavioral domains common in dementia. Higher scores indicate more severe illness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in suicidal ideation and behavior as measured by the Sheehan Suicidality Tracking Scale (S-STS)</measure>
    <time_frame>Subjects will be followed up to 14 days post-dose</time_frame>
    <description>Sheehan Suicidality Tracking Scale (S-STS) is a 16-item scale that assesses the seriousness of suicidality phenomena on a likert-type scale (0 to 4) ranging from 0 = not at all to 4 = extremely</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in motor complications as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 4</measure>
    <time_frame>Subjects will be followed up to 14 days post-dose</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 4 includes 6 items assessing motor complications, higher scores indicate more serious illness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total score of the Sheehan Suicidality Tracking Scale (S-STS)</measure>
    <time_frame>Subjects will be followed up to 14 days post-dose</time_frame>
    <description>Sheehan Suicidality Tracking Scale (S-STS) is a 16-item scale that assesses the seriousness of suicidality phenomena on a likert-type scale (0 to 4) ranging from 0 = not at all to 4 = extremely</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the One Back test</measure>
    <time_frame>Week 12</time_frame>
    <description>The One Back test is a measure of working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Two Back test</measure>
    <time_frame>Week 12</time_frame>
    <description>The Two Back test is a measure of working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Groton Maze Learning Test</measure>
    <time_frame>Week 12</time_frame>
    <description>The Groton Maze Learning test is a measure of problem solving and reasoning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Identification Test</measure>
    <time_frame>Week 12</time_frame>
    <description>The Identification test is a measure of visual attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the International Shopping List Test</measure>
    <time_frame>Week 12</time_frame>
    <description>The International Shopping List test is a measure of verbal learning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on Continuous Paired Associate Learning Test</measure>
    <time_frame>Week 12</time_frame>
    <description>The Continuous Paired Associate Learning test is a measure of visual associate memory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Mild Dementia</condition>
  <condition>Parkinson Disease</condition>
  <condition>Lewy Body Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NYX-458 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose taken daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Matching placebo capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NYX-458</intervention_name>
    <description>NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).</description>
    <arm_group_label>NYX-458 30 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent&#xD;
&#xD;
          -  Diagnosis of Parkinson's disease and mild cognitive impairment or mild dementia OR&#xD;
             diagnosis of mild cognitive impairment or mild dementia with Lewy bodies&#xD;
&#xD;
          -  Presence of subjective cognitive complaints by the patient&#xD;
&#xD;
          -  Verifiable impairment, as defined a CGI-S (Clinical Global Impression-Severity) score&#xD;
             of at least 3 (mildly ill).&#xD;
&#xD;
          -  Score on the MoCA (Montreal Cognitive Assessment) between 15 and 25, inclusive.&#xD;
&#xD;
          -  Stable anti-parkinsonian regimen (if applicable)&#xD;
&#xD;
          -  Has a study partner who can accompany the subject at specified study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically meaningful motor complications&#xD;
&#xD;
          -  Current use of medications with primarily central nervous system activities&#xD;
&#xD;
          -  Other clinically significant medical histories that may interfere with completing the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aptinyx Clinical Development</last_name>
    <phone>847-871-0377</phone>
    <phone_ext>1</phone_ext>
    <email>clinicalstudies@aptinyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Reseda</city>
        <state>California</state>
        <zip>91335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Port Royal</city>
        <state>South Carolina</state>
        <zip>29935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

